Journal of Korean Medicine for Obesity Research (한방비만학회지)

The Society of Korean Medicine for obesity Research (한방비만학회)
권호 표지
DOI QR코드

DOI QR Code

Gamitaeeumjowee-tang for Weight Loss in Overweight and Obese Women with Polycystic Ovary Syndrome: A Retrospective Chart Review

과체중 또는 비만인 다낭성 난소 증후군 환자의 체중감량을 위한 가미태음조위탕의 활용: 후향적 차트 리뷰

  • Received : 2022.10.25
  • Accepted : 2022.11.25
  • Published : 2022.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: The objective of this study is to evaluate weight change and analyze adverse events in overweight and obese women with polycystic ovary syndrome (PCOS) who were prescribed with Gamitaeeumjowee-tang. Methods: A retrospective chart review was conducted for medical records of patients with PCOS, who were administered with Gamitaeeumjowee-tang for a period of 12 weeks between January 2019 and December 2021. Outcomes were total weight loss/weight loss rate, the percentage of patients who lost more than 5% and 10% of their baseline weight. Adverse events (AEs) reported by patients were evaluated by severity, causality and system-organ classes. Results: A total of sixty-seven patients were included (mean±standard deviation, Age 28.78±5.25 years, weight 76.78±12.84 kg, body mass index 29.2±4.26 kg/m2). The average total weight loss in PCOS patients was 6.57±3.07 kg and the average weight loss rate was 8.55±3.65%. The percentage of patients with more than 5% and 10% weight loss compared to their baseline weight was 86.56% and 25.37% respectively. The analysis of adverse events are as follows: Causality assessment with World Health Organization-Uppsala Monitoring Centre of AEs showed 'Unlikely' was the most common (71.7%) and severity evaluations with Common Terminology Criteria for Adverse Events showed almost all symptoms were mild (98.9%). Conclusions: Gamitaeeumjowee-tang helps to lose weight of PCOS patients, which is overweight or obese, and no serious adverse events have occurred. Additional well-designed clinical studies are recommended.

Keywords

References

  1. Min WG. Polycystic ovary syndrome. J Korean Obstet Gynecol. 2008 ; 51(8) : 805-19.
  2. Korean Society of Obstetrics and Gynecology. Gynecology. 5th ed. Seoul : Korea Medical Book Publishing Company (KOMB). 2015 : 488.
  3. Byun EG, Kim HJ, Oh JY, Hong YS, Sung YA. The prevalence of polycystic ovary syndrome in college students from Seoul. Journal of Korean Endocrine Society. 2005 ; 20(2) : 120-6. https://doi.org/10.3803/jkes.2005.20.2.120
  4. Health Insurance Review & Assessment Service. Healthcare Bigdata Hub [Internet]. 2022 [cited 2022 Oct 26]. Available from: https://opendata.hira.or.kr/op/opc/olap4thDsInfo.do.
  5. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000 ; 52 : 595-600. https://doi.org/10.1046/j.1365-2265.2000.01000.x
  6. Kim JJ, Hwang KR, Choi YM, Moon SY, Chae SJ, Park CW, et al. Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome. Fertil Steril. 2014 ; 101(5) : 1424-30. https://doi.org/10.1016/j.fertnstert.2014.01.049
  7. Thmas MB, Petra H, Martin OW, Stephen F. Obestiy and polycystic overy syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019 ; 13 : 1179558119874042.
  8. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995 ; 80 : 2586-93. https://doi.org/10.1210/jc.80.9.2586
  9. Moran L, Norman RJ. Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004 ; 18(5) : 719-36. https://doi.org/10.1016/j.bpobgyn.2004.05.003
  10. Mamaru AA, Arul E, Anju EJ, Allison MH, Helena JT, Wendy JB, et al. Weight gain and lifestyle factors in women with and without polycystic ovary syndrome. Human Reproduction. 2022 ; 37(1) : 129-41.
  11. Linden HA, Naessen S, Stridsberg M, Bystrom B, Holte J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol. 2004 ; 19 : 79-87. https://doi.org/10.1080/09513590400002300
  12. Georgopoulos NA, Saltamavros AD, Vervita V, Karkoulias K, Adonakis G, Decavalas G, et al. Basal metabolic rate is decreased in womenwith polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. Fertil Steril. 2009 ; 92 : 250-5. https://doi.org/10.1016/j.fertnstert.2008.04.067
  13. Robinson S, Chan SP, Spacey S, Anyaoku V, Johnston DG, Franks S. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol. 1992 ; 36 : 537-43. https://doi.org/10.1111/j.1365-2265.1992.tb02262.x
  14. Hellas C, Luca C, Rossella EN. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endotrinl Metab. 2020 ; 105(8) : e2695-709. https://doi.org/10.1210/clinem/dgaa285
  15. Cho YJ, Lee YJ, Ahn YT, Kang ES, Kim HJ, Hong DH, et al. A review of the clinical study trends on Korean medicine treatment for polycystic ovary syndrome. J Korean Obstet Gynecol. 2022 ; 35(2) : 87-105.
  16. Park SH, Lee JM, Lee CH, Jang JB, Hwang DS. Analysis of the characteristics and treatment of polycystic ovary syndrome patients in a Korean medicine hospital. J Korean Obstet Gynecol. 2019 ; 32(1) : 37-47.
  17. Shin HG, Bae JY, Ji YG, Ahn HI, Yoon YH, Kim NK. A case series of polycystic ovary syndrome with improved hyperandrogenism treated with Korean medicine. J Korean Obstet Gynecol. 2021 ; 34(3) : 175-91. https://doi.org/10.15204/JKOBGY.2021.34.3.175
  18. Kim DH. A case study on obese patient with oligomenorrhea and polycystic ovary. J Korean Med Obes Res. 2008 ; 8(1) : 101-8.
  19. Lee JS. A case study on infertility with obesity and polycystic ovary. J Korean Med Obes Res. 2005 ; 5(1) : 157-63.
  20. Korea Institute of Drug Safety & Risk Reaction Management. Adverse Drug Assessment Report. 1st ed. Seoul : Korea Institute of Drug Safety & Risk Management. 2013 : 60-3.
  21. National Cancer Institute, National Institute of Health, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Internet]. 2009 [cited 2009 May 29]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
  22. Korea Institute of Drug Safety & Risk Management. Terminology guide for reporting adverse drug reactions. Seoul : Korea Institute of Drug Safety & Risk Management. 2014 : 1-6.
  23. Legro RS, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Williams NI, et al. Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015 ; 100 : 4048-58. https://doi.org/10.1210/jc.2015-2778
  24. European Society of Human Reproduction and Embryology; The Thessaloniki, and ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008 ; 23 : 462-77. https://doi.org/10.1093/humrep/dem426
  25. Dapas M, Lin FTJ, Nadkarni GN, Sick R, Legro RS, Urbanek M, et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis. PLoS Med. 2020 ; 17(6) : e1003132.
  26. Kang EY, Park YJ, Kim MJ, Park YB. A study on factors associated with weight loss by 'Gamitaeeumjowee-tang'. J Korean Med Obes Res. 2017 ; 17(2) : 68-72. https://doi.org/10.15429/jkomor.2017.17.2.68
  27. Lee A, Lee DY, Kim MJ, Lee HS, Choi KH, Kim SY, et al. Gamitaeeumjowee-tang for weight loss in diabetic patients: a retrospective chart review. J Korean Med. 2021 ; 42(1) : 46-57. https://doi.org/10.13048/jkm.21004
  28. Yoon NR, Yoo YJ, Kim MJ, Kim SY, Lim YW, Lim HH, et al. Analysis of adverse events in weight loss program in combination with 'Gamitaeeumjowee-tang' and low-calorie diet. J Korean Med Obes Res. 2018 ; 18(1) : 1-9. https://doi.org/10.15429/jkomor.2018.18.1.1
  29. Park YJ, Cominguez DC, Kim HJ, Jin JS, Koh DJ, Kim SY, et al. Therapeutic effects of Gambi-jung for the treatment of obesity. Biomedicine & Pharmacotherapy. 2021; 141 : 111838.
  30. Javed Z, Papageorgiou M, Dexhmukh H, Rigby AS, Qamar U, Abbas J, et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol (Oxf). 2019 ; 90(6) : 805-13. https://doi.org/10.1111/cen.13968
  31. Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021 ; 134(23) : 2882-9. https://doi.org/10.1097/CM9.0000000000001712
  32. Azadi-Yazdi M, Karimi-Zarchi M, Salehi-Abargouei A, Fallahzadeh H, Nadjaradeh A. Effects of dietary approach to stop hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. J Hum Nutr Diet. 2017 ; 30(3) : 275-83. https://doi.org/10.1111/jhn.12433
  33. Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity-focused on RCT. J Korean Med. 2017 ; 38(3) : 170-84. https://doi.org/10.13048/jkm.17034
  34. Christensen P, Bliddal H, Riecke BF, Leeds AR, Astrup A, Christensen R. Comparison of a low-energy diet and a very low-energy diet in sedentary obese individuals: a pragmatic randomized controlled trial. Obes. 2011 ; 1(1) : 31-40.